The audience is advised that this continuing medical education activity may contain references to unlabeled uses of Food and Drug Administration (FDA) -approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Planning Committee and Faculty members report the following relationship(s):

Marc C. Chamberlain, MD, Chair

Professor of Neurology, University of Washington, Department of Neurology and Neurological Surgery, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington

Disclosures

Disclosure: Consulting Fees: Genentech, Roche, Exelixis; Fees for Non-CME Services Received Directly From Commercial Interest or Their Agents: Genentech, Roche, Exelixis.

David A. Reardon, MD

Associate Professor, Departments of Surgery and Pediatrics, Associate Deputy Director, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina

Disclosures

Disclosure: Consulting Fees: EMD Serono, Merck, Schering, Genentech, Roche.

Patrick Y. Wen, MD

Director, Neuro-Oncology, Professor of Neurology, Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts

Disclosures

Disclosure: Consulting Fees: Ark Therapeutics, Agios, Genzyme, Novartis, Imclone/Lilly; Contract Research: Boehringer Ingelheim, Amgen, Astra Zeneca, Esai, Exelixis, Genentech, Merck, Novartis.

External reviewer reports the following relationship(s):

Mark R. Gilbert, MD

Disclosures

Disclosure: Consulting Fees: Abbott, Merck, Genentech, Tau.

Vindico and HEMONC TODAY staff report the following relationship(s):
No relevant financial relationships to disclose.

Scheduled speakers for Understanding the Clinical Applicability of Integrin Inhibition in the Treatment of Glioblastoma have provided the above disclosure information, which is accurate at the time of release of this activity.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

CME

Understanding the Clinical Applicability of Integrin Inhibition in the Treatment of Glioblastoma

Authors: Marc C. Chamberlain, MD, Chair; David A. Reardon, MD; Patrick Y. Wen, MD
CME Released: 4/15/2011
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 4/15/2012, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity was developed for oncologists, hematologists/oncologists, oncology nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Integrins play a crucial role in tumor signaling, survival, migration, and angiogenesis, making them potent targets for cancer therapy, particularly for gliomas and glioblastomas. Several integrin inhibitors are being studied and have been shown to be effective with minimal side effects. This activity will provide an overview of integrin biology and the role of anti-integrins in the treatment of glioblastomas.

Upon completion of this activity, participants should be able to:

Describe the mechanism of action of integrin inhibitors in the treatment of gliomas and glioblastomas.
Evaluate preclinical and clinical data on the efficacy and safety of integrin inhibitors.
Identify and enroll appropriate patients in suitable ongoing clinical trials that evaluate integrin inhibitors, alone and in combination with other therapies, for the treatment of gliomas and glioblastomas.

Disclosures

Planning Committee and Faculty members report the following relationship(s):

Marc C. Chamberlain, MD, Chair

Professor of Neurology, University of Washington, Department of Neurology and Neurological Surgery, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington

Disclosures

Disclosure: Consulting Fees: Genentech, Roche, Exelixis; Fees for Non-CME Services Received Directly From Commercial Interest or Their Agents: Genentech, Roche, Exelixis.

David A. Reardon, MD

Associate Professor, Departments of Surgery and Pediatrics, Associate Deputy Director, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina

Disclosures

Disclosure: Consulting Fees: EMD Serono, Merck, Schering, Genentech, Roche.

Patrick Y. Wen, MD

Director, Neuro-Oncology, Professor of Neurology, Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts

Disclosures

Disclosure: Consulting Fees: Ark Therapeutics, Agios, Genzyme, Novartis, Imclone/Lilly; Contract Research: Boehringer Ingelheim, Amgen, Astra Zeneca, Esai, Exelixis, Genentech, Merck, Novartis.

External reviewer reports the following relationship(s):

Mark R. Gilbert, MD

Disclosures

Disclosure: Consulting Fees: Abbott, Merck, Genentech, Tau.

Accreditation Statements

For Physicians

This continuing education activity is jointly-sponsored by HEMONC TODAY® and Vindico Medical Education.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of HEMONC TODAY® and Vindico Medical Education. Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Vindico Medical Education designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For the purpose of recertifying with the American Nurses Credentialing Center, AMA PRA Category 1 CME Credits™ from organizations accredited by ACCME can be used.

This enduring material is approved for 1 year from the date of original release.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

processing....

Download Slides

This CME activity was developed to be distributed on Medscape and HEMONC TODAY® Education Lab, and to be developed into a CME monograph that will mail in the June issue of HEMONC TODAY®.

This feature requires the newest version of Flash. You can download it here.

CME Information

Print
Like Tweet

Disclaimer

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on www.medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

© 2011 Created and published by Vindico Medical Education 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Copyright© 2011 Slack Incorporated. All rights reserved. No part of this activity may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and HEMONC TODAY® continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and HEMONC TODAY®. Neither Vindico Medical Education, HEMONC TODAY® nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the United States Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Faculty and Disclosures

Marc C. Chamberlain, MD, Chair

David A. Reardon, MD

Patrick Y. Wen, MD

Mark R. Gilbert, MD

CME

Understanding the Clinical Applicability of Integrin Inhibition in the Treatment of Glioblastoma

Target Audience and Goal Statement

Disclosures

Marc C. Chamberlain, MD, Chair

David A. Reardon, MD

Patrick Y. Wen, MD

Mark R. Gilbert, MD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Understanding the Clinical Applicability of Integrin Inhibition in the Treatment of Glioblastoma